{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-021926","form_type":"8-K","ticker":"INFU","cik":"0001337013","company_name":"InfuSystem Holdings, Inc","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.008699+00:00","generated_at":"2026-06-02T05:12:25.863207+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"InfuSystem reports Q1 revenue up 5% to $32.0M; net loss widens, reaffirms guidance","bullets":["Net revenues of $32.0M (+5% YoY); record quarterly revenue.","Gross margin improved to 51.5% from 49.2%; gross profit +10%.","Net loss widened to $1.1M ($0.05/share) from $0.3M ($0.02) a year ago.","Adjusted EBITDA fell 9% to $3.9M, with margin of 12.1% vs 13.9%.","FY 2024 guidance reaffirmed: high-single-digit revenue growth, high-teens EBITDA margin."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-021926","json":"https://secwatch.observer/filing/0001628280-24-021926.json","markdown":"https://secwatch.observer/filing/0001628280-24-021926.md","text":"https://secwatch.observer/filing/0001628280-24-021926.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1337013/000162828024021926/0001628280-24-021926-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1337013/000162828024021926/infu-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T05:12:25.863207+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f83480db8ecfb0f47f0e8a4451cb021529359231","claim":"InfuSystem Holdings, Inc reported first quarter ended March 31, 2024 results: revenue Net revenues totaled $32.0 million, net income Net loss was $1.1 million, EPS $(0.05) per diluted share.","evidence_excerpt":"• Net revenues totaled $32.0 million, an increase of 5% vs. prior year. ◦ Patient Services net revenue was $18.6 million, a decrease of 1% vs. prior year. ◦ Device Solutions net revenue was $13.4 million, an increase of 16% vs. prior year. • Gross profit was $16.5 million, an increase of 10% vs. prior year. • Gross margin was 51.5%, an increase of 2.3% vs. prior year. ◦ Patient Services gross margin was 66.0%, an increase of 4.5% vs. prior year. ◦ Device Solutions gross margin was 31.3%, an increase of 1.9% vs. prior year. • Net loss was $1.1 million, or $(0.05) per diluted share vs. prior year net loss of $0.3 million, or $(0.02) per diluted share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1337013/000162828024021926/0001628280-24-021926-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"Net revenues totaled $32.0 million"},{"label":"Net income","value":"Net loss was $1.1 million"},{"label":"EPS","value":"$(0.05) per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}